Figure 1
From: Safety of rituximab in the treatment of B cell malignancies: implications for rheumatoid arthritis
Incidence of treatment related adverse events in the pivotal study of rituximab in relapsed and refractory indolent non-Hodgkin's lymphoma, stratified by infusion number. From McLaughlin and coworkers [13]. Reprinted with permission from the American Society of Clinical Oncology.